Metrics to compare | 4891 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship4891PeersSector | |
|---|---|---|---|---|
P/E Ratio | −9.9x | −10.0x | −0.6x | |
PEG Ratio | −0.26 | −0.05 | 0.00 | |
Price/Book | 2.5x | 3.6x | 2.6x | |
Price / LTM Sales | - | 23.6x | 3.2x | |
Upside (Analyst Target) | 307.9% | 122.4% | 48.1% | |
Fair Value Upside | Unlock | 5.1% | 5.8% | Unlock |
TMS Co., Ltd. engages in the research and development, manufacture, and sale of drug products, quasi-drugs, drug substances, medical devices, and medical commodities. The company is developing TMS-007, a stachybotrys microspora triprenyl phenol (SMTP) congener with prothrombolytic and anti-inflammatory/antioxidative activities, which has completed Phase 2a clinical trials for acute ischemic stroke treatment; and TMS-008, an SMTP congener with anti-inflammatory/antioxidative activities under nonclinical development for inflammatory complications, such as acute kidney injury and cancer cachexia. It is also developing TMS-009, a product candidate in preclinical development. In addition, the company has a collaboration with Hokkaido University to evaluate the potential of the drug candidate compounds as novel drugs. TMS Co., Ltd. was incorporated in 2005 and is headquartered in Fuchu, Japan.